Kratzke RA - Search Results

1

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

Govindan R, Kratzke RA, Herndon JE 2nd, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL; Cancer and Leukemia Group B (CALGB 30101). Govindan R, et al. Among authors: kratzke ra. Clin Cancer Res. 2005 Mar 15;11(6):2300-4. doi: 10.1158/1078-0432.CCR-04-1940. Clin Cancer Res. 2005. PMID: 15788680 Clinical Trial.

2

Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade.

Jain A, Zhang S, Shanley RM, Fujioka N, Kratzke RA, Patel MR, Kulkarni AA. Jain A, et al. Among authors: kratzke ra. Cancer Immunol Immunother. 2023 May;72(5):1225-1232. doi: 10.1007/s00262-022-03320-3. Epub 2022 Nov 16. Cancer Immunol Immunother. 2023. PMID: 36383245 Free PMC article.

3

Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.

Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Geradts J, et al. Among authors: kratzke ra. Cancer Res. 1995 Dec 15;55(24):6006-11. Cancer Res. 1995. PMID: 8521382

4

Rb and p16INK4a expression in resected non-small cell lung tumors.

Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, Geradts J. Kratzke RA, et al. Cancer Res. 1996 Aug 1;56(15):3415-20. Cancer Res. 1996. PMID: 8758904

5

Human lung carcinomas express Fas ligand.

Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA. Niehans GA, et al. Among authors: kratzke ra. Cancer Res. 1997 Mar 15;57(6):1007-12. Cancer Res. 1997. PMID: 9067260

6

Do molecular markers predict survival in non-small-cell lung cancer?

Greatens TM, Niehans GA, Rubins JB, Jessurun J, Kratzke RA, Maddaus MA, Niewoehner DE. Greatens TM, et al. Among authors: kratzke ra. Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1093-7. doi: 10.1164/ajrccm.157.4.9707108. Am J Respir Crit Care Med. 1998. PMID: 9563724

7

Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.

Gupta P, Niehans GA, LeRoy SC, Gupta K, Morrison VA, Schultz C, Knapp DJ, Kratzke RA. Gupta P, et al. Among authors: kratzke ra. Leukemia. 1999 Jan;13(1):44-53. doi: 10.1038/sj.leu.2401233. Leukemia. 1999. PMID: 10049059

8

G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder.

Niehans GA, Kratzke RA, Froberg MK, Aeppli DM, Nguyen PL, Geradts J. Niehans GA, et al. Among authors: kratzke ra. Br J Cancer. 1999 Jun;80(8):1175-84. doi: 10.1038/sj.bjc.6990483. Br J Cancer. 1999. PMID: 10376969 Free PMC article.

9

Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis.

Lickliter JD, Kratzke RA, Nguyen PL, Niehans GA, Miller JS. Lickliter JD, et al. Among authors: kratzke ra. Exp Hematol. 1999 Oct;27(10):1519-27. doi: 10.1016/s0301-472x(99)00091-0. Exp Hematol. 1999. PMID: 10517493 Free article.

10

Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer.

Zhou JX, Niehans GA, Shar A, Rubins JB, Frizelle SP, Kratzke RA. Zhou JX, et al. Among authors: kratzke ra. Lung Cancer. 2001 Apr;32(1):27-38. doi: 10.1016/s0169-5002(00)00210-5. Lung Cancer. 2001. PMID: 11282426

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

155 results

Search Page

Filters